Skip to main content
. 2021 Jun 23;40(30):4906–4918. doi: 10.1038/s41388-021-01891-6

Fig. 1. Expression of sorcin (SRI) in PTX-resistant ovarian cancer.

Fig. 1

A Heatmap showed the top ten upregulated and downregulated mRNAs in paclitaxel-resistant OV3R-PTX cells compared with paclitaxel-sensitive OVCAR-3 cells by a cutoff value of more than 2-fold. B Top ten upregulated mRNAs in the microarray were confirmed by qRT-PCR. ***, p < 0.001. C Analysis of the top 50 upregulated mRNAs and proteins from transcriptomes and proteomics. SRI and MDR1 were overexpressed both at mRNA and protein levels in OV3R-PTX cells. D SRI protein expression in OVCAR-3 and OV3R-PTX cells detected by Western blot. E SRI protein expression in SKOV-3 and SK3R-PTX cells detected by Western blot. F Immunofluorescence staining of SRI in OVCAR-3 and OV3R-PTX cells. G Immunofluorescence staining of SRI in SKOV3 and SK3R-PTX cells. H Representative images of SRI protein expression in primary ovarian cancer and non-tumorous ovarian tissue by immunohistochemistry. Original magnification, ×20. I Comparison of SRI protein expression between non-tumorous ovarian tissues (n = 9) and OC tissues (n = 20). J Comparison of SRI mRNA expression between chemotherapy-sensitive (n = 16) and chemotherapy-resistant (n = 12) ovarian serous carcinoma. K Kaplan–Meier analysis of the overall survival of OC patients associated with SRI expression. L Kaplan–Meier analysis of the progression-free survival of OC patients associated with SRI expression.